Tianchen Bio Completes Series A+2 Financing to Accelerate Pipeline Development in Autoimmune Diseases

VCBeat (WeChat: vcbeat) learned at the earliest opportunity that, recently,LongBio Pharma (Suzhou) Co., Ltd.(hereinafter referred to as ""LongBio") announced the completion of aYongshi CapitalAdditionalSeries A+2Financing. This marks another round of additional investment for the company, following its completion of a tens-of-millions-yuan A+1 financing round in August this year.

Dr. Heng Liu, General Manager of LongBioIt was announced that the Company’s first Class I biological new drug, LP-003, enrolled its first subject in Phase I clinical trials and completed dosing in September. In late September, the second Class I biological new drug, LP-001, also officially commenced clinical trials. With two projects in its pipeline simultaneously in the clinical stage, the Company has entered a new phase of development. At this significant historical milestone, the successive additional investments secured by the Company fully demonstrate the confidence of all parties, including Yongshi Investment, in its future growth. The Company will remain committed to its original mission, forge ahead, and deliver greater clinical benefits to patients worldwide.

LongBio is dedicated to addressing unmet clinical needs in autoimmune diseases, with a strategic portfolio targeting multiple pathways in allergy and complement systems. Its pipeline features potential first-in-class and best-in-class therapeutics poised to fill significant global clinical gaps. Leveraging deep insights into the clinical and market demands of autoimmune disorders, the company has developed a suite of highly differentiated next-generation large-molecule antibodies by capitalizing on its high-performance antibody platform. Supported by this round of financing, LongBio will accelerate Phase I clinical trials and preclinical studies of its pipeline candidates, further expanding its R&D portfolio and enhancing its technological platforms.

The Company will continue to uphold the philosophy of “creating a true Chinese blockbuster product,” accelerate the commercialization of its products, and deliver breakthrough innovative therapies to patients at an earlier date.

The company is headquartered in the Changshu High-Tech Zone of Jiangsu Province, with its R&D center located in the Zhangjiang Hi-Tech Park in Shanghai. Dr. Heng Liu, a co-founder, brings extensive experience in new drug development. Since returning to China after completing his doctoral studies, he has led and participated in the research and development, industrialization, and market launch of multiple biologics filed for approval in both China and the United States. Another co-founder, Dr. Naichao Sun, is one of the inventors of Omalizumab and was involved in founding Tanox, Inc., a U.S.-based company listed on Nasdaq that was later acquired by Genentech. The core technical team members have decades of deep industry experience, accumulating substantial practical expertise in the research and development of biologics. The company’s pipeline focuses on unmet clinical needs in the field of autoimmune diseases, with several candidates already in clinical trials. Moving forward, the company will continue to advance clinical studies and expand its preclinical pipeline to deliver greater clinical benefits to patients.

Yongshi Capital, established in March 2012, is the first private equity fund in Huzhou City specializing in equity investment. The funds it manages are primarily focused on strategic emerging industries supported by major national policies, including the big health industry, new energy, information technology, and high-end equipment manufacturing. To date, it has invested in more than 20 projects, with eight of them in the big health sector, including Zhejiang Orient Gene Biotech Co., Ltd., Shanghai Yudu Medical Technology Co., Ltd., Hangzhou Zhiwei Information Technology Co., Ltd., and LongBio Pharma (Suzhou) Co., Ltd. Leveraging professional investment judgment, extensive experience, standardized operations, and differentiated investment strategies, Yongshi Capital ranked 85th in the Top 100 list of domestic VC/PE firms by exit return rate in 2021.